Arcus Biosciences Stock Performance
| RCUS Stock | USD 21.03 1.00 4.99% |
Arcus Biosciences has a performance score of 3 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.065, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Arcus Biosciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Arcus Biosciences is expected to be smaller as well. Arcus Biosciences right now shows a risk of 4.06%. Please confirm Arcus Biosciences downside variance, and the relationship between the total risk alpha and daily balance of power , to decide if Arcus Biosciences will be following its price patterns.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Arcus Biosciences are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Arcus Biosciences may actually be approaching a critical reversion point that can send shares even higher in March 2026. ...more
Actual Historical Performance (%)
One Day Return 0.48 | Five Day Return (3.95) | Year To Date Return (9.27) | Ten Year Return 24.29 | All Time Return 24.29 |
1 | Arcus Biosciences NYSE Composite Shows Biotech Energy | 11/20/2025 |
2 | Disposition of 5000 shares by Goeltz Ii Robert C. of Arcus Biosciences at 25.0 subject to Rule 16b-3 | 11/26/2025 |
3 | Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its RD Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio | 12/12/2025 |
4 | Disposition of 28947 shares by Terry Rosen of Arcus Biosciences at 21.8843 subject to Rule 16b-3 | 12/16/2025 |
5 | Arcus Biosciences Reassessing Valuation After Domvanalimab Trial Discontinuation and Casdatifan Pipeline Shift | 12/23/2025 |
6 | Disposition of 2400 shares by Terry Rosen of Arcus Biosciences subject to Rule 16b-3 | 12/30/2025 |
7 | Disposition of 6552 shares by Goeltz Ii Robert C. of Arcus Biosciences at 23.38 subject to Rule 16b-3 | 12/31/2025 |
8 | Arcus Biosciences President Sells 2 Million as Stock Delivers 48 percent Annual Return | 01/06/2026 |
9 | Disposition of 35000 shares by Terry Rosen of Arcus Biosciences subject to Rule 16b-3 | 01/08/2026 |
10 | Arcus Biosciences Cut to Sell at Wall Street Zen | 01/13/2026 |
11 | Wall Street Zen Upgrades Arcus Biosciences to Hold | 01/20/2026 |
12 | Arcus Biosciences, Inc. Analyst Consensus Signals 51 percent Upside Potential Amid Robust Clinical Pipeline - DirectorsTalk Interviews | 01/30/2026 |
| Begin Period Cash Flow | 130 M | |
| Total Cashflows From Investing Activities | -84 M |
Arcus Biosciences Relative Risk vs. Return Landscape
If you would invest 2,000 in Arcus Biosciences on November 12, 2025 and sell it today you would earn a total of 103.00 from holding Arcus Biosciences or generate 5.15% return on investment over 90 days. Arcus Biosciences is currently generating 0.1672% in daily expected returns and assumes 4.0609% risk (volatility on return distribution) over the 90 days horizon. In different words, 36% of stocks are less volatile than Arcus, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Arcus Biosciences Target Price Odds to finish over Current Price
The tendency of Arcus Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 21.03 | 90 days | 21.03 | about 75.87 |
Based on a normal probability distribution, the odds of Arcus Biosciences to move above the current price in 90 days from now is about 75.87 (This Arcus Biosciences probability density function shows the probability of Arcus Stock to fall within a particular range of prices over 90 days) .
Arcus Biosciences Price Density |
| Price |
Predictive Modules for Arcus Biosciences
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Arcus Biosciences. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Arcus Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Arcus Biosciences Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Arcus Biosciences is not an exception. The market had few large corrections towards the Arcus Biosciences' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Arcus Biosciences, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Arcus Biosciences within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.11 | |
β | Beta against Dow Jones | 0.07 | |
σ | Overall volatility | 1.88 | |
Ir | Information ratio | 0.01 |
Arcus Biosciences Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Arcus Biosciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Arcus Biosciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Arcus Biosciences had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 258 M. Net Loss for the year was (283 M) with loss before overhead, payroll, taxes, and interest of (263 M). | |
| Arcus Biosciences currently holds about 1.05 B in cash with (170 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.48. | |
| Roughly 61.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Arcus Biosciences, Inc. Analyst Consensus Signals 51 percent Upside Potential Amid Robust Clinical Pipeline - DirectorsTalk Interviews |
Arcus Biosciences Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Arcus Stock often depends not only on the future outlook of the current and potential Arcus Biosciences' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Arcus Biosciences' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 90.1 M | |
| Cash And Short Term Investments | 978 M |
Arcus Biosciences Fundamentals Growth
Arcus Stock prices reflect investors' perceptions of the future prospects and financial health of Arcus Biosciences, and Arcus Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Arcus Stock performance.
| Return On Equity | -0.68 | ||||
| Return On Asset | -0.21 | ||||
| Profit Margin | (1.42) % | ||||
| Operating Margin | (5.46) % | ||||
| Current Valuation | 1.88 B | ||||
| Shares Outstanding | 123.73 M | ||||
| Price To Earning | 27.69 X | ||||
| Price To Book | 5.97 X | ||||
| Price To Sales | 10.84 X | ||||
| Revenue | 258 M | ||||
| Gross Profit | (263 M) | ||||
| EBITDA | (269 M) | ||||
| Net Income | (283 M) | ||||
| Cash And Equivalents | 1.05 B | ||||
| Cash Per Share | 14.48 X | ||||
| Total Debt | 60 M | ||||
| Debt To Equity | 0.17 % | ||||
| Current Ratio | 6.22 X | ||||
| Book Value Per Share | 4.07 X | ||||
| Cash Flow From Operations | (170 M) | ||||
| Earnings Per Share | (3.42) X | ||||
| Market Capitalization | 2.6 B | ||||
| Total Asset | 1.15 B | ||||
| Retained Earnings | (1.13 B) | ||||
| Working Capital | 790 M | ||||
About Arcus Biosciences Performance
Assessing Arcus Biosciences' fundamental ratios provides investors with valuable insights into Arcus Biosciences' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Arcus Biosciences is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.22) | (0.23) | |
| Return On Capital Employed | (0.41) | (0.43) | |
| Return On Assets | (0.22) | (0.23) | |
| Return On Equity | (0.67) | (0.70) |
Things to note about Arcus Biosciences performance evaluation
Checking the ongoing alerts about Arcus Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Arcus Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Arcus Biosciences had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 258 M. Net Loss for the year was (283 M) with loss before overhead, payroll, taxes, and interest of (263 M). | |
| Arcus Biosciences currently holds about 1.05 B in cash with (170 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.48. | |
| Roughly 61.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Arcus Biosciences, Inc. Analyst Consensus Signals 51 percent Upside Potential Amid Robust Clinical Pipeline - DirectorsTalk Interviews |
- Analyzing Arcus Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Arcus Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Arcus Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Arcus Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Arcus Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Arcus Biosciences' stock. These opinions can provide insight into Arcus Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Arcus Stock Analysis
When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.